(Q37523616)

20 August 2017

title

Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study (English)

1 reference

20 August 2017

1 reference

6

Cora N Sternberg

1 reference

20 August 2017

David J Vaughn

1

1 reference

20 August 2017

Sandy Srinivas

2

1 reference

20 August 2017

Walter M Stadler

3

1 reference

20 August 2017

Roberto Pili

4

1 reference

20 August 2017

Daniel Petrylak

5

1 reference

20 August 2017

David C Smith

7

1 reference

20 August 2017

Sarah Ringuette

8

1 reference

20 August 2017

Edwin de Wit

9

1 reference

20 August 2017

Virginie Pautret

10

1 reference

20 August 2017

Claude George

11

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 September 2009

1 reference

20 August 2017

number of pages

8

1 reference

inferred from page(s)

published in

Cancer

1 reference

20 August 2017

volume

115

1 reference

20 August 2017

issue

18

1 reference

20 August 2017

page(s)

4110-4117

1 reference

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24460

7 January 2021

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24460

7 January 2021

Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24460

7 January 2021

Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24460

7 January 2021

Systemic chemotherapy for advanced bladder cancer: update and controversies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24460

7 January 2021

Therapy of metastatic bladder carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24460

7 January 2021

VincaAlkaloids in Superacidic Media: A Method for Creating a New Family of Antitumor Derivatives

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24460

7 January 2021

Modifications in the "upper" velbenamine part of the Vinca alkaloids have major implications for tubulin interacting activities

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24460

7 January 2021

Superior in vivo experimental antitumour activity of vinflunine, relative to vinorelbine, in a panel of human tumour xenografts

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24460

7 January 2021

Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated Vinca alkaloid

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24460

7 January 2021

Higher antitumor activity of vinflunine than vinorelbine against an orthotopic murine model of transitional cell carcinoma of the bladder.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24460

7 January 2021

A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24460

7 January 2021

Vinflunine: a novel antitubulin agent in solid malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24460

7 January 2021

Identifiers

DOI

10.1002/CNCR.24460

1 reference

20 August 2017

1 reference